ARDS Clinical Trial
— ARDSOfficial title:
Effects of Sedation on Transpulmonary Pressure and Lung Homogenous of ARDS Patients
Verified date | March 2018 |
Source | Southeast University, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The acute respiratory distress syndrome (ARDS) is characterized by severe respiratory failure. Open Lung and Lung Protective Strategy have been proved to improve mortality of ARDS patients. Preserving spontaneous breathing (SB) is good for inflating the lung lobe near diaphram during mechanical ventilation, however, strong respiratory drive could generate more transpulmonary pressure in ARDS patients, which increase the stress and strain in injured lung. Nonetheless, it's not clear if sedative has any effects on transpulmonary pressure of ARDS patients.The purpose of this study is to investigate the effects of sedation on transpulmonary pressure of ARDS patients.
Status | Completed |
Enrollment | 24 |
Est. completion date | March 18, 2018 |
Est. primary completion date | January 18, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. ARDS group patient (1) Acute onset of all of the following criteria within a 48-hour period: 1. Requires positive pressure ventilation through an endotracheal tube 2. Bilateral infiltrates consistent with edema on frontal chest radiograph, with a duration of no more than 7 days 3. PaO2/FiO2 less than 300 while receiving positive end-expiratory pressure (PEEP) at more than 5 cm H2O for at least 4 hours, with a duration of no more than 7 days 4. No clinical evidence of left atrial hypertension (2) Hemodynamics stable (dopamine <10ug/kg•min or norepinephrine <10ug/kg) 2. Surgical patient Surgical patient requires positive pressure ventilation through an endotracheal tube PaO2/FiO2 more than 300 Hemodynamics stable (dopamine <10ug/kg•min or norepinephrine <10ug/kg) Exclusion Criteria: - Age younger than 18 years or older than 85 years - Cardiac failure - Known pregnancy - Increased intracranial pressure - Severe neuromuscular disease - Recent injury or other pathologic condition of the esophagus - Pneumothorax - Pleural effusion - Diaphragmatic hernia - Severe chronic respiratory disease - End-stage chronic organ failure - Expected survival of less than 24 hours - Participation in another interventional study - Attending physician declines to give consent for participant to enroll - Patient or surrogate declines or is unable to give consent |
Country | Name | City | State |
---|---|---|---|
China | Department of Critical Care Medicine, Nanjing Zhong-da Hospital, School of Medicine, Southeast University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Southeast University, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | MAP | MAP during deep or light sedation | 15 minutes | |
Primary | Transpulmonary pressure generate by patient during deep or light sedation | Ispiratory transpulmonary pressure and expiratory transpulmonary pressure measured during sedation | 15 minutes during deep or light sedation | |
Secondary | static compliance of respiratory system | Crs measured during deep or light sedation | 15min during deep or light sedation | |
Secondary | PaO2 | ABG after deep or light sedation | 15 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |